相似文献
1
US Food and Drug Administration gets it right.
BMJ. 2002 Oct 5;325(7367):776. doi: 10.1136/bmj.325.7367.776.
2
Coxibs and cardiovascular disease.
N Engl J Med. 2004 Oct 21;351(17):1709-11. doi: 10.1056/NEJMp048288. Epub 2004 Oct 6.
3
COX-2 inhibitors--lessons in drug safety.
N Engl J Med. 2005 Mar 17;352(11):1133-5. doi: 10.1056/NEJMe058042. Epub 2005 Feb 15.
4
Reporting of clinical trials of analgesia.
J Thorac Cardiovasc Surg. 2004 Feb;127(2):605; author reply 606. doi: 10.1016/j.jtcvs.2003.08.038.
5
COX-2 inhibitors--a lesson in unexpected problems.
N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15.
6
Second selective COX-2 inhibitor receives marketing approval.
Am J Health Syst Pharm. 1999 Jul 1;56(13):1294. doi: 10.1093/ajhp/56.13.1294a.
7
[Cyclooxygenase inhibitors: a never ending story?].
G Ital Cardiol (Rome). 2006 Jul;7(7):505-7.
8
Parecoxib, valdecoxib, and cardiovascular risk.
Circulation. 2005 Jan 25;111(3):249. doi: 10.1161/01.CIR.0000155081.76164.17. Epub 2005 Jan 17.
9
Arthritis medicines and cardiovascular events--"house of coxibs".
JAMA. 2005 Jan 19;293(3):366-8. doi: 10.1001/jama.293.3.366. Epub 2004 Dec 28.
10
Raising the safety bar--the FDA's coxib meeting.
N Engl J Med. 2005 Mar 31;352(13):1283-5. doi: 10.1056/NEJMp058055.
本文引用的文献
1
NICE needs sweeping changes to maintain credibility, say MPs. National Institute for Clinical Excellence.
BMJ. 2002 Jul 6;325(7354):5. doi: 10.1136/bmj.325.7354.5.
2
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
BMJ. 2002 Jun 1;324(7349):1287-8. doi: 10.1136/bmj.324.7349.1287.
Zotero 插件